Pham Phuong-Thu T, Slavov Carmen, Pham Phuong-Chi T
Department of Medicine, Nephrology Division, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA 90095, USA.
Adv Chronic Kidney Dis. 2009 Jul;16(4):256-67. doi: 10.1053/j.ackd.2009.04.002.
Recipients of nonrenal organ transplants including the liver, heart, and lung are at risk for developing acute kidney injury (AKI) and chronic kidney disease (CKD). Underlying hepatic or cardiopulmonary failure, prolonged intraoperative hemodynamic instability, and the use of calcineurin inhibitors and nephrotoxic medications have all been suggested to be contributory. The incidence of perioperative AKI has been reported to occur in 17% to 95% in liver transplant recipients, 5% to 30% in heart transplant recipients, and 5% to 60% in recipients of lung transplants. Among those who develop AKI, renal replacement therapy is required in 5% to 35%, 5% to 15%, and 8% to 10% in liver, heart, and lung transplant recipients, respectively. The current article presents an overview of the literature on the choice of dialysis modality and its associated advantages and disadvantages in the management of AKI after liver, heart, and lung transplants. Predictive factors for renal function recovery and the impact of AKI and CKD on survival will also be discussed.
接受包括肝脏、心脏和肺在内的非肾器官移植的患者有发生急性肾损伤(AKI)和慢性肾脏病(CKD)的风险。潜在的肝或心肺功能衰竭、术中长时间的血流动力学不稳定以及使用钙调神经磷酸酶抑制剂和肾毒性药物均被认为是导致发病的因素。据报道,肝移植受者围手术期AKI的发生率为17%至95%,心脏移植受者为5%至30%,肺移植受者为5%至60%。在发生AKI的患者中,肝、心脏和肺移植受者分别有5%至35%、5%至15%和8%至10%需要进行肾脏替代治疗。本文概述了有关肝、心脏和肺移植后AKI管理中透析方式选择及其相关优缺点的文献。还将讨论肾功能恢复的预测因素以及AKI和CKD对生存的影响。